STOCK TITAN

[4] – Parkman Healthcare Partners LLC (CIK 0001777015)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Spruce Biosciences (SPRB) — Form 4 insider trading update. Parkman Healthcare Partners LLC and Gregory Martinez reported trades on 10/06/2025 as indirect owners. They purchased 256 shares of common stock at a weighted average price of $17.9108 (within $17.55–$18.00), then sold 232 shares at $19.3264 (within $19.125–$19.63) and sold 25 shares at $17.4557 (within $17.44–$17.56). Following the reported transactions, they beneficially owned 1,050 shares indirectly through private funds. Each reporting person disclaims beneficial ownership beyond pecuniary interest.

Spruce Biosciences (SPRB) — aggiornamento Form 4 sull'insider trading. Parkman Healthcare Partners LLC e Gregory Martinez hanno riportato operazioni il 06/10/2025 in qualità di proprietari indiretti. hanno acquistato 256 azioni ordinarie a un prezzo medio ponderato di $17,9108 (nell'intervallo $17,55–$18,00), poi venduto 232 azioni a $19,3264 (nell'intervallo $19,125–$19,63) e venduto 25 azioni a $17,4557 (nell'intervallo $17,44–$17,56). A seguito delle operazioni riportate, detengono beneficiariamente 1.050 azioni indirettamente tramite fondi privati. Ciascun soggetto riportante rinuncia alla proprietà beneficiaria oltre l'interesse pecuniario.

Spruce Biosciences (SPRB) — actualización de operaciones de insider trading Form 4. Parkman Healthcare Partners LLC y Gregory Martinez informaron operaciones el 10/06/2025 como propietarios indirectos. Compraron 256 acciones de acciones ordinarias a un precio medio ponderado de $17,9108 (en el rango 17,55–18,00), luego vendieron 232 acciones a $19,3264 (dentro de 19,125–19,63) y vendieron 25 acciones a $17,4557 (dentro de 17,44–17,56). Después de las transacciones reportadas, poseían beneficiariamente 1.050 acciones indirectamente a través de fondos privados. Cada parte informante renuncia a la propiedad beneficiaria más allá de su interés pecuniario.

Spruce Biosciences (SPRB) — Form 4 내부자 거래 업데이트. Parkman Healthcare Partners LLC 및 Gregory Martinez는 간접 소유자로서 2025-10-06에 거래를 보고했습니다. 그들은 256주를 매수했으며 가중평균가 $17.9108 (범위 17.55–18.00)로, 이어 232주를 매도 $19.3264 (범위 19.125–19.63) 그리고 25주를 매도 $17.4557 (범위 17.44–17.56)했다. 보고된 거래 후, 그들은 개인 펀드를 통해 간접적으로 1,050주를 유리하게 보유하게 되었습니다. 각 보고 당사자는 재산상의 이익 주권을 넘어선 소유권을 포기합니다.

Spruce Biosciences (SPRB) — mise à jour Form 4 sur le trading d'initiés. Parkman Healthcare Partners LLC et Gregory Martinez ont signalé des transactions en tant que propriétaires indirects le 06/10/2025. Ils ont acheté 256 actions ordinaires à un prix moyen pondéré de $17,9108 (dans la fourchette $17,55–$18,00), puis ont vendu 232 actions à $19,3264 (dans $19,125–$19,63) et ont vendu 25 actions à $17,4557 (dans $17,44–$17,56). À la suite des transactions signalées, ils détiennent bénéficiairement 1 050 actions indirectement par le biais de fonds privés. Chaque partie signalante déclare renoncer à la propriété bénéficiaire au-delà de son intérêt pécuniaire.

Spruce Biosciences (SPRB) — Form 4 Insider-Handels-Update. Parkman Healthcare Partners LLC und Gregory Martinez meldeten im 10.06.2025 Geschäfte als indirekte Eigentümer. Sie kauften 256 Aktien der Stammaktie zu einem gewichteten Durchschnittspreis von $17,9108 (im Bereich von $17,55–$18,00), dann verkauften 232 Aktien zu $19,3264 (im Bereich von $19,125–$19,63) und verkauften 25 Aktien zu $17,4557 (im Bereich von $17,44–$17,56). Nach den gemeldeten Transaktionen besaßen sie insgesamt 1.050 Aktien indirekt über Privatinvestments. Jede meldende Person erklärt, über ihr finanzielles Interesse hinaus keinen Eigentumsanspruch zu haben.

Spruce Biosciences (SPRB) — تحديث Form 4 لتداول داخلي. أفاد Parkman Healthcare Partners LLC و Gregory Martinez بعمليات كمالكين غير مباشرين في 10/06/2025. اشتروا 256 سهماً من الأسهم العادية بسعر متوسط مرجح قدره $17.9108 (ضمن النطاق $17.55–$18.00)، ثم باعوا 232 سهماً بسعر $19.3264 (ضمن $19.125–$19.63) وباعوا 25 سهماً بسعر $17.4557 (ضمن $17.44–$17.56). عقب المعاملات المبلغ عنها، أصبحوا مالكـين مستفيدين 1,050 سهماً بشكل غير مباشر من خلال صناديق خاصة. يقر كل شخص مُبلّغ به بأنه يتنصل من الملكية المستفيدة بما يتجاوز مصلحته المالية.

Spruce Biosciences (SPRB) — Form 4 内幕交易更新。 Parkman Healthcare Partners LLC 与 Gregory Martinez 以间接所有者身份在 2025/10/06 报告交易。他们 买入了 256 股普通股,加权平均价格为 $17.9108(区间在 $17.55–$18.00 之间),随后 以 $19.3264 出售 232 股(区间在 $19.125–$19.63)以及 以 $17.4557 出售 25 股(区间在 $17.44–$17.56)。在所报告的交易之后,他们通过私募基金间接持有 1,050 股。每位报备人都否认对股份有超出其金钱利益的受益所有权。

Positive
  • None.
Negative
  • None.

Spruce Biosciences (SPRB) — aggiornamento Form 4 sull'insider trading. Parkman Healthcare Partners LLC e Gregory Martinez hanno riportato operazioni il 06/10/2025 in qualità di proprietari indiretti. hanno acquistato 256 azioni ordinarie a un prezzo medio ponderato di $17,9108 (nell'intervallo $17,55–$18,00), poi venduto 232 azioni a $19,3264 (nell'intervallo $19,125–$19,63) e venduto 25 azioni a $17,4557 (nell'intervallo $17,44–$17,56). A seguito delle operazioni riportate, detengono beneficiariamente 1.050 azioni indirettamente tramite fondi privati. Ciascun soggetto riportante rinuncia alla proprietà beneficiaria oltre l'interesse pecuniario.

Spruce Biosciences (SPRB) — actualización de operaciones de insider trading Form 4. Parkman Healthcare Partners LLC y Gregory Martinez informaron operaciones el 10/06/2025 como propietarios indirectos. Compraron 256 acciones de acciones ordinarias a un precio medio ponderado de $17,9108 (en el rango 17,55–18,00), luego vendieron 232 acciones a $19,3264 (dentro de 19,125–19,63) y vendieron 25 acciones a $17,4557 (dentro de 17,44–17,56). Después de las transacciones reportadas, poseían beneficiariamente 1.050 acciones indirectamente a través de fondos privados. Cada parte informante renuncia a la propiedad beneficiaria más allá de su interés pecuniario.

Spruce Biosciences (SPRB) — Form 4 내부자 거래 업데이트. Parkman Healthcare Partners LLC 및 Gregory Martinez는 간접 소유자로서 2025-10-06에 거래를 보고했습니다. 그들은 256주를 매수했으며 가중평균가 $17.9108 (범위 17.55–18.00)로, 이어 232주를 매도 $19.3264 (범위 19.125–19.63) 그리고 25주를 매도 $17.4557 (범위 17.44–17.56)했다. 보고된 거래 후, 그들은 개인 펀드를 통해 간접적으로 1,050주를 유리하게 보유하게 되었습니다. 각 보고 당사자는 재산상의 이익 주권을 넘어선 소유권을 포기합니다.

Spruce Biosciences (SPRB) — mise à jour Form 4 sur le trading d'initiés. Parkman Healthcare Partners LLC et Gregory Martinez ont signalé des transactions en tant que propriétaires indirects le 06/10/2025. Ils ont acheté 256 actions ordinaires à un prix moyen pondéré de $17,9108 (dans la fourchette $17,55–$18,00), puis ont vendu 232 actions à $19,3264 (dans $19,125–$19,63) et ont vendu 25 actions à $17,4557 (dans $17,44–$17,56). À la suite des transactions signalées, ils détiennent bénéficiairement 1 050 actions indirectement par le biais de fonds privés. Chaque partie signalante déclare renoncer à la propriété bénéficiaire au-delà de son intérêt pécuniaire.

Spruce Biosciences (SPRB) — Form 4 Insider-Handels-Update. Parkman Healthcare Partners LLC und Gregory Martinez meldeten im 10.06.2025 Geschäfte als indirekte Eigentümer. Sie kauften 256 Aktien der Stammaktie zu einem gewichteten Durchschnittspreis von $17,9108 (im Bereich von $17,55–$18,00), dann verkauften 232 Aktien zu $19,3264 (im Bereich von $19,125–$19,63) und verkauften 25 Aktien zu $17,4557 (im Bereich von $17,44–$17,56). Nach den gemeldeten Transaktionen besaßen sie insgesamt 1.050 Aktien indirekt über Privatinvestments. Jede meldende Person erklärt, über ihr finanzielles Interesse hinaus keinen Eigentumsanspruch zu haben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Parkman Healthcare Partners LLC

(Last) (First) (Middle)
700 CANAL STREET

(Street)
STAMFORD CT 06902

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value per share 10/06/2025 P 256 A $17.9108(1) 1,307 I See footnote(2)
Common Stock, $0.001 par value per share 10/06/2025 S 232 D $19.3264(3) 1,075 I See footnote(2)
Common Stock, $0.001 par value per share 10/06/2025 S 25 D $17.4557(4) 1,050 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Parkman Healthcare Partners LLC

(Last) (First) (Middle)
700 CANAL STREET

(Street)
STAMFORD CT 06902

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Martinez Gregory

(Last) (First) (Middle)
700 CANAL STREET

(Street)
STAMFORD CT 06902

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $17.55 to $18. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
2. The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $19.125 to $19.63. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $17.44 to $17.56. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
As previously disclosed in Parkman Healthcare Partners LLC's Form 4 with respect to the Issuer filed on October 8, 2025, these securities are also indirectly beneficially owned by Gregory Martinez.
Parkman Healthcare Partners LLC, By: /s/ Gregory Martinez, Chief Investment Officer 10/15/2025
/s/ Gregory Martinez 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SPRB insiders report on Form 4?

Parkman Healthcare Partners LLC and Gregory Martinez reported indirect purchases and sales of SPRB common stock on 10/06/2025.

How many SPRB shares were bought and at what price?

They bought 256 shares at a weighted average price of $17.9108 within a range of $17.55–$18.00.

How many SPRB shares were sold and at what prices?

They sold 232 shares at a weighted average of $19.3264 (range $19.125–$19.63) and 25 shares at $17.4557 (range $17.44–$17.56).

What is the post-transaction indirect ownership for SPRB?

Following the reported transactions, the reporting persons indirectly beneficially owned 1,050 shares.

Were these holdings direct or indirect?

Indirect. The filing states the position is held through private funds, with beneficial ownership disclaimed beyond pecuniary interest.

Who are the reporting persons in this SPRB Form 4?

The form was filed by Parkman Healthcare Partners LLC and Gregory Martinez (Chief Investment Officer), as more than one reporting person.
Spruce Biosciences, Inc.

NASDAQ:SPRB

SPRB Rankings

SPRB Latest News

SPRB Latest SEC Filings

SPRB Stock Data

88.25M
550.44k
2.32%
21.05%
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO